Sponsor:
Shine-On Biomedical Co., Ltd.
Code:
NCT07219940
Conditions
Healthy Subjects
Exosome
Targeted Therapy
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Interventions
SOB100
Brief summary:
Conditions
Healthy Subjects
Exosome
Targeted Therapy
Study ID
NCT07219940
Start date
Dec 1, 2025
Status verified date
Oct, 2025
Completion date
Mar, 2027
Anticipated
Primary completion date
Dec, 2026
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Accepted
Enrollment
15 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: SOB100
Interventions
SOB100
Primary outcome measure
Central contacts
Oscar Yang
rd009@shineon-bio.comLocations
Parexel International - Baltimore Early Phase Clinical Unit
Recruiting
Baltimore, Maryland, United States, 21225
Contacts
Sponsor
Shine-On Biomedical Co., Ltd.
Last update posted
Jan 26, 2026
Last verified
Oct, 2025
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Shine-On Biomedical Co., Ltd. on 2026-01-26.